Human botulism immune globulin for the treatment of infant botulism

New England Journal of Medicine

Volumn 354, Issue 5, 2006, Pages 462-471

  Arnon, Stephen S ^a,d   Schechter, Robert ^a   Maslanka, Susan E ^b   Jewell, Nicholas P ^c   Hatheway, Charles L ^b  

^a Infant Botulism Treatment and Prevention Program   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN A; BOTULINUM TOXIN B; HUMAN BOTULISM IMMUNOGLOBULIN; HUMAN IMMUNOGLOBULIN; ORPHAN DRUG; PLACEBO; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; ASPIRATION PNEUMONIA; BACTEREMIA; BOTULISM; CHILD HOSPITALIZATION; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM TYPE A; CLOSTRIDIUM BOTULINUM TYPE B; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; FEMALE; FRACTURE; HOSPITAL ADMISSION; HOSPITAL CHARGE; HOSPITAL COST; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; HYPOTHERMIA; INFANT; INFANT DISEASE; INTENSIVE CARE; INTESTINE; INTRAVENOUS FEEDING; LABORATORY; LENGTH OF STAY; LONG BONE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OTITIS MEDIA; OUTCOME ASSESSMENT; PNEUMOMEDIASTINUM; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY ARREST; RESPIRATORY DISTRESS SYNDROME; SEIZURE; SEPTIC SHOCK; SUBCUTANEOUS EMPHYSEMA; TOXEMIA; TOXIC MEGACOLON; TRACHEA STENOSIS; TREATMENT DURATION; TUBE FEEDING; UNITED STATES; URINARY TRACT INFECTION; VIRAL BRONCHIOLITIS;

BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; BOTULISM; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; LENGTH OF STAY; MALE; TREATMENT OUTCOME;

EID: 32044452414     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa051926     Document Type: Article

References (27)

1. Botulism in the United States, 1899-1996: handbook for epidemiologists, clinicians, and laboratory workers. Atlanta: Centers for Disease Control and Prevention, 1998. (Accessed January 6, 2006, at http://www.bt.cdc.gov/agent/ botulism/index. asp.)
2. Wilcke BW Jr, Midura TF, Arnon SS.Quantitative evidence of intestinal colonization by Clostridium botulinum in four cases of infant botulism. J Infect Dis 1980; 141:419-23.
3. Arnon SS, Midura TF, Clay SA, Wood RM, Chin J. Infant botulism: epidemiological, clinical, and laboratory aspects. JAMA 1977;237:1946-51.
4. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000;80:717-66.
5. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-93.
6. Long SS, Gajewski JL, Brown LW, Gilligan PH. Clinical, laboratory, and environmental features of infant botulism in southeastern Pennsylvania. Pediatrics 1985;75:935-41.
7. Schreiner MS, Field E, Ruddy R. Infant botulism: a review of 12 years' experience at the Children's Hospital of Philadelphia. Pediatrics 1991;87:159-65.
8. Nevas M, Lindstrom M, Virtanen A, et al. Infant botulism acquired from household dust presenting as sudden infant death syndrome. J Clin Microbiol 2005;43:511-3.
9. Arnon SS. Infant botulism. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, eds. Textbook of pediatric infectious diseases. 5th ed. Philadelphia: W.B. Saunders, 2004:1758-66.
10. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982;46:86-94.
11. Barash JR, Tang TWH, Arnon SS. First case of infant botulism caused by Clostridium baratii type F in California. J Clin Microbiol 2005;43:4280-2.
12. Barash JR, Arnon SS. Dual toxin-producing strain of Clostridium botulinum type Bf isolated from a California patient with infant botulism. J Clin Microbiol 2004;42:1713-5.
13. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980;69:567-70.
14. Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE Jr. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis 1984;150:407-12.
15. Outbreak of hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 1994;43:505-9.
16. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: John Wiley, 1980.
17. Arnon SS, Midura TF, Damus K, Thompson B, Wood RM, Chin J. Honey and other environmental risk factors for infant botulism. J Pediatr 1979;94:331-6.
18. Arnon SS, Damus K, Thompson B, Midura TF, Chin J. Protective role of human milk against sudden death from infant botulism. J Pediatr 1982;100:568-73.
19. Schechter R, Peterson B, McGee J, Idowu O, Bradley J. Clostridium difficile colitis associated with infant botulism: near-fatal case analogous to Hirschsprung's enterocolitis. Clin Infect Dis 1999;29:367-74.
20. Fenicia L, Da Dalt L, Anniballi F, Franciosa G, Zanconato S, Aureli P. A case of infant botulism due to neurotoxigenic Clostridium butyricum type E associated with Clostridium difficile colitis. Eur J Clin Microbiol Infect Dis 2002;21:736-8.
21. Johnson RO, Clay SA, Arnon SS. Diagnosis and management of infant botulism. Am J Dis Child 1979;133:586-93.
22. Cooper MS. Antitoxins to C. botulinum. In: Lewis KH, Cassel K Jr, eds. Botulism: proceedings of a symposium. Cincinnati: Public Health Service, 1964:147-64. (USPHS publication no. 999-FP-1.)
23. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984;76:794-8.
24. Chang GY, Ganguly G. Early antitoxin treatment in wound botulism results in better outcome. Eur Neurol 2003;49:151-3.
25. 42 Code of Federal Regulations, Part 73. Possession, use and transfer of select agents and toxins (final rule). Fed Regist 2005;70:13294-325.
26. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059-70.
27. Nowakowski A, Wang C, Powers DB, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002;99:11346-50.